0001140361-23-051047.txt : 20231102 0001140361-23-051047.hdr.sgml : 20231102 20231102111538 ACCESSION NUMBER: 0001140361-23-051047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231102 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 231370723 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 ef20013902_8k.htm 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  November 2, 2023
 
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
000-19125
  
33-0336973
(Commission File No.)
  
(IRS Employer Identification No.)

2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
 
Registrant’s telephone number, including area code: (760) 931-9200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading symbol
  
Name of each exchange on which registered
Common Stock, $.001 Par Value
   “IONS”
  
The Nasdaq Stock Market, LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
  Emerging growth company                ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
Item 2.02
Results of Operations and Financial Condition.
 
On November 2, 2023, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023.  In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows.  A copy of the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
 
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
Description
Press Release dated November 2, 2023.
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Ionis Pharmaceuticals, Inc.
     
Dated:  November 2, 2023
By:
/s/ Patrick R. O’Neil
   
Patrick R. O’Neil
   
Executive Vice President, Chief Legal
Officer and General Counsel


EX-99.1 2 ef20013902_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


Ionis reports third quarter 2023 financial results
 
Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients with FCS; on track for regulatory filings in early 2024
 
Eplontersen marketing applications accepted for review in the EU and Canada; potential U.S. approval in December 2023
 
On track to achieve 2023 financial guidance
 
CARLSBAD, Calif., November 2, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the third quarter of 2023.
 
“We continue to successfully execute on our strategy to deliver a steady cadence of potentially transformational medicines to patients,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Eplontersen is on track for its first potential approval in the U.S. and is under regulatory review in the EU and Canada. We believe the positive efficacy and safety data coupled with an attractive self-administration dosing profile positions eplontersen to be the preferred therapy in the largely underserved hereditary ATTR polyneuropathy population. We reported positive data from the olezarsen Phase 3 Balance study in patients with familial chylomicronemia syndrome, showing statistically significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability, positioning olezarsen to be our first independent commercial launch. We also made additional progress across our wholly owned and partnered pipeline, and further expanded our rich Phase 3 pipeline with the advance of zilganersen for patients with Alexander disease into Phase 3 development. Looking ahead, we expect to continue our positive momentum with the potential approval and launch of eplontersen and the Phase 3 data readout of donidalorsen in hereditary angioedema.”
 
Third Quarter 2023 Summary Financial Results:
 
   
Three months ended
September 30,
    
Nine months ended
September 30,
  
   
2023
    
2022
    
2023
    
2022
  
   
(amounts in millions)
  
Total revenue
  
$
144
    
$
160
    
$
463
    
$
435
  
Operating expenses
  
$
287
    
$
219
    
$
811
    
$
637
  
Operating expenses on a non-GAAP basis
  
$
261
    
$
195
    
$
732
    
$
562
  
Loss from operations
  
$ 
(143
)
  
$ 
(59
)
  
$ 
(348
)
  
$ 
(202
)
Loss from operations on a non-GAAP basis
  
$ 
(117
)
  
$ 
(35
)
  
$ 
(269
)
  
$ 
(127
)

1
Financial Highlights

•
Revenue continued to be substantial and sustained, with revenues of $144 million and $463 million in the three and nine months ended September 30, 2023, reflecting a 10% decrease and 6% increase compared to the same periods last year, respectively, driven by the timing of certain partner payments
 
•
Operating expenses increased in the three and nine months ended September 30, 2023 compared to the same periods last year, primarily due to strategic investments to bring eplontersen, olezarsen and donidalorsen to patients
 
•
Cash and short-term investments of $2.2 billion as of September 30, 2023 enables continued investments to drive increasing value
 
•
Reaffirmed 2023 financial guidance
 
Near-Term Commercial Opportunities and Late-Stage Pipeline Highlights

•
Achieved multiple milestones with eplontersen:
 

 o
Eplontersen is under regulatory review by the European Medicines Agency (EMA) and Health Canada for the treatment of hereditary ATTR polyneuropathy (ATTRv-PN)
 

 o
The EMA granted orphan drug designation to eplontersen for the treatment of ATTR in the EU
 

 o
Published positive data from the Phase 3 NEURO-TTRansform study in patients with ATTRv-PN in the Journal of the American Medical Association (JAMA) showing eplontersen halted measures of disease progression and continuously improved quality of life at 35-, 66- and 85-weeks
 

 o
Presented positive new data showing continued benefit in secondary endpoints from the Phase 3 NEURO-TTRansform study in patients with ATTRv-PN at the European ATTR Amyloidosis (EU-ATTR) meeting
 

 o
Presented positive exploratory data from a pre-defined cardiac sub-population of patients in NEURO-TTRansform showing improvement in cardiac function and structure compared to external placebo at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
 

 o
Completed enrollment of the Phase 3 CARDIO-TTRansform study of eplontersen in patients with ATTR cardiomyopathy (ATTR-CM), the largest study ever conducted in ATTR-CM; on track for data readout as early as H1:2025
 
•
Reported positive data from the Phase 3 Balance study of olezarsen in patients with familial chylomicronemia syndrome (FCS)
 

 o
Olezarsen demonstrated robust, dose-dependent reductions in APOCIII, statistically significant reductions in triglycerides, substantial reductions in acute pancreatitis attacks and a favorable safety and tolerability profile
 

 o
On track to file for regulatory approval in the U.S. and EU in early 2024
 
•
The FDA granted orphan drug designation to donidalorsen for the treatment of patients with hereditary angioedema (HAE); on track for data readout in the Phase 3 OASIS-HAE study in H1:2024
 
•
Advanced zilganersen (GFAP) into Phase 3 development for the treatment of patients with Alexander disease
 
2
•
The FDA granted orphan drug designation to ulefnersen (FUS) for the treatment of patients with FUS-ALS
 
Partnered Program Highlights

•
GSK reported positive data from the Phase 2b B-Together study of bepirovirsen followed by pegylated interferon in patients with chronic hepatitis B virus (HBV)
 
•
Reported positive interim data from the ongoing Phase 2 study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN)
 
•
Biogen reported positive data from the Phase 1/2 study of IONIS-MAPTRx (BIIB080) in patients with Alzheimer’s disease
 
•
Completed enrollment in the Phase 1/2 HALOS study of ION582 (BIIB121) in patients with Angelman syndrome
 
•
Entered a new agreement with Roche to advance two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease
 
3
Third Quarter 2023 Financial Results
 
“Our year-to-date financial results keep us on track to achieve our 2023 guidance as we execute on a strategy to unlock next-level value,” said Elizabeth L. Hougen, chief financial officer of Ionis. “Our strong financial foundation includes more than $2B in cash, significant royalty revenue with SPINRAZA, and substantial and sustained R&D revenue from multiple partners. We are well positioned to continue investing in our key priorities to drive future positive cash flow, including advancing our go-to-market activities, growing our wholly owned pipeline and optimizing new cutting-edge technologies for future medicines. We look forward to the potential U.S. eplontersen ATTRv-PN approval next month followed closely by launch. Together with our partner, AstraZeneca, we believe we are well positioned to identify new patients to further grow the market and become the treatment of choice for this population that remains largely underserved by current therapies.”
 
Revenue

Ionis’ revenue was comprised of the following:

   
Three months ended
September 30,
    
Nine months ended
September 30,
  
   
2023
    
2022
    
2023
    
2022
  
Revenue:
  
(amounts in millions)
  
Commercial revenue:
                        
SPINRAZA royalties
  
$
67
    
$
62
    
$
179
    
$
175
  
Other commercial revenue:
                                
TEGSEDI and WAYLIVRA revenue, net
    
8
      
6
      
25
      
23
  
Licensing and royalty revenue
    
9
      
5
      
26
      
25
  
Total commercial revenue
    
84
      
73
      
230
      
223
  
Research and development revenue:
                                
Amortization from upfront payments
    
18
      
18
      
47
      
54
  
Milestone payments
    
16
      
15
      
90
      
60
  
License fees
    
5
      
35
      
25
      
37
  
Other services
    
5
      
1
      
11
      
6
  
Collaborative agreement revenue
    
44
      
69
      
173
      
157
  
Eplontersen joint development revenue
    
16
      
18
      
60
      
55
  
Total research and development revenue
    
60
      
87
      
233
      
212
  
Total revenue
  
$
144
    
$
160
    
$
463
    
$
435
  

Commercial revenue for the three and nine months ended September 30, 2023 included $67 million and $179 million from SPINRAZA royalties, respectively, which were essentially flat compared to the same periods last year reflecting SPINRAZA’s resilience against emerging competition. Ionis’ commercial revenue in the three and nine months ended September 30, 2023 also included royalties from the U.S. launch of QALSODY.

R&D revenue decreased for the three months ended September 30, 2023 and increased for the nine months ended September 30, 2023 compared to the same periods last year due to the timing of certain partner payments, including the $35 million license fee for IONIS-FB-LRx that Ionis earned from Roche in the three months ended September 30, 2022.

4
Operating Expenses
 
Ionis’ operating expenses increased in the three and nine months ended September 30, 2023 compared to the same periods in 2022, consistent with expectations. As Ionis advanced its robust pipeline, study costs increased compared to the same periods in 2022 as most of the Company’s Phase 3 studies are either fully enrolled or approaching full enrollment, resulting in higher R&D expenses year over year. Ionis’ SG&A expenses also increased year over year primarily due to launch preparation activities for eplontersen, olezarsen and donidalorsen.

Balance Sheet

As of September 30, 2023, Ionis’ cash, cash equivalents and short-term investments increased to $2.2 billion compared to $2.0 billion at December 31, 2022 primarily due to the $500 million Ionis received from Royalty Pharma in January 2023. Ionis’ working capital also increased over the same period primarily due to the Company’s higher cash and short-term investments balance. In the first quarter of 2023, the Company recorded a long-term liability for future royalties due to Royalty Pharma. In June 2023, Ionis issued $575 million of senior convertible notes due in June 2028 with an interest rate of 1.75%.  The Company used the majority of the proceeds to repurchase $504 million of its 0.125% convertible notes.

Webcast

Management will host a conference call and webcast to discuss Ionis’ third quarter 2023 results at 11:30 a.m. Eastern time on Thursday, November 2, 2023. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company’s third quarter 2023 earnings slides click here.

About Ionis Pharmaceuticals, Inc.
 
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

To learn more about Ionis visit www.ionispharma.com or follow us on Twitter @ionispharma.

Ionis’ Forward-looking Statement
 
This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of QALSODY (tofersen), SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen), eplontersen, olezarsen, donidalorsen, zilganersen, ulefnersen, pelacarsen, bepirovirsen, IONIS-FB-LRx, Ionis' technologies and Ionis’ other products in development. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2022, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

5
In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. QALSODYTM is a trademark of Biogen. SPINRAZA® is a registered trademark of Biogen.

Ionis Investor Contact:
D. Wade Walke, Ph.D.
info@ionisph.com 760-603-2331

Ionis Media Contact:
David Polk, J.D.
ionis_ca@ionisph.com 760-603-4679

6
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Millions, Except Per Share Data)

   
Three months ended,
September 30,
    
Nine months ended
September 30,
  
   
2023
    
2022
    
2023
    
2022
  
   
(unaudited)
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
67
    
$
62
    
$
179
    
$
175
  
Other commercial revenue
    
17
      
11
      
51
      
48
  
Total commercial revenue
    
84
      
73
      
230
      
223
  
Research and development revenue:
                                
Collaborative agreement revenue
    
44
      
69
      
173
      
157
  
Eplontersen joint development revenue
    
16
      
18
      
60
      
55
  
Total research and development revenue
    
60
      
87
      
233
      
212
  
Total revenue
    
144
      
160
      
463
      
435
  
Expenses:
                                
Cost of sales
    
2
      
2
      
6
      
10
  
Research, development and patent
    
215
      
183
      
643
      
525
  
Selling, general and administrative
    
70
      
34
      
162
      
102
  
Total operating expenses
    
287
      
219
      
811
      
637
  
Loss from operations
    
(143
)
    
(59
)
    
(348
)
    
(202
)
                                 
Other income (expense):
                                
Interest expense related to the sale of future royalties:
    
(18
)
    
-
      
(51
)
    
-
  
Other income (expense), net
    
20
      
12
      
68
      
(12
)
Loss before income tax expense
    
(141
)
    
(47
)
    
(331
)
    
(214
)
                                 
Income tax expense
    
(6
)
    
-
      
(26
)
    
(3
)
                                 
Net loss
  
$ 
(147
)
  
$ 
(47
)
  
$ 
(357
)
  
$ 
(217
)
                                 
Basic and diluted net loss per share
  
$ 
(1.03
)
  
$ 
(0.33
)
  
$ 
(2.50
)
  
$ 
(1.53
)
Shares used in computing basic and diluted net loss per share
    
143
      
142
      
143
      
142
  

7
IONIS PHARMACEUTICALS, INC.
Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss
(In Millions)

   
Three months ended
September 30,
    
Nine months ended
September 30,
  
   
2023
    
2022
    
2023
    
2022
  
   
(unaudited)
  
As reported research, development and patent expenses according to GAAP
  
$
215
    
$
183
    
$
643
    
$
525
  
Excluding compensation expense related to equity awards
    
(19
)
    
(18
)
    
(58
)
    
(55
)
Non-GAAP research, development and patent expenses
  
$
196
    
$
165
    
$
585
    
$
470
  
                                 
 
As reported selling, general and administrative expenses according to GAAP
  
$
70
    
$
34
    
$
162
    
$
102
  
Excluding compensation expense related to equity awards
    
(7
)
    
(6
)
    
(22
)
    
(19
)
Non-GAAP selling, general and administrative expenses
  
$
63
    
$
28
    
$
140
    
$
83
  
                                 
As reported operating expenses according to GAAP
  
$
287
    
$
219
    
$
811
    
$
637
  
Excluding compensation expense related to equity awards
    
(26
)
    
(24
)
    
(79
)
    
(75
)
Non-GAAP operating expenses
  
$
261
    
$
195
    
$
732
    
$
562
  
                                 
As reported loss from operations according to GAAP
  
$ 
(143
)
  
$ 
(59
)
  
$ 
(348
)
  
$ 
(202
)
Excluding compensation expense related to equity awards
    
(26
)
    
(24
)
    
(79
)
    
(75
)
Non-GAAP loss from operations
  
$ 
(117
)
  
$ 
(35
)
  
$ 
(269
)
  
$ 
(127
)
                                 
As reported net loss according to GAAP
  
$ 
(147
)
  
$ 
(47
)
  
$ 
(357
)
  
$ 
(217
)
Excluding compensation expense related to equity awards and related tax effects
    
(26
)
    
(24
)
    
(79
)
    
(75
)
Non-GAAP net loss
  
$ 
(121
)
  
$ 
(23
)
  
$ 
(278
)
  
$ 
(142
)

Reconciliation of GAAP to Non-GAAP Basis
 
As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.
 
8
IONIS PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
(In Millions)

   
September 30,2023
    
December 31,2022
  
   
(unaudited)
        
Assets:
            
Cash, cash equivalents and short-term investments
  
$
2,236
    
$
1,987
  
Contracts receivable
    
142
      
26
  
Other current assets
    
207
      
190
  
Property, plant and equipment, net
    
71
      
74
  
Right-of-use assets
    
174
      
182
  
Other assets
    
104
      
75
  
Total assets
    
2,934
    
$
2,534
  
                 
Liabilities and stockholders’ equity:
                
Other current liabilities
  
$
199
    
$
221
  
Current portion of deferred contract revenue
    
205
      
91
  
1.75% convertible senior notes, net
    
562
      
-
  
0% convertible senior notes, net
    
625
      
622
  
0.125% convertible senior notes, net
    
44
      
545
  
Liability related to sale of future royalties, net
    
513
      
-
  
Long-term lease liabilities
    
173
      
178
  
Long-term obligations, less current portion
    
49
      
16
  
Long-term deferred contract revenue
    
249
      
288
  
Total stockholders’ equity
    
315
      
573
  
Total liabilities and stockholders’ equity
  
$
2,934
    
$
2,534
  

9
Key 2023 Value Driving Events(1)
 
Regulatory Actions
Program
Indication
Regulatory Action
Achieved
QALSODY
SOD1-ALS
NDA approval
EU approval2
  
Eplontersen (TTR)
ATTRv-PN
NDA approval
  
OUS filings

Key Clinical Data Events
Program
Indication
Event
Achieved
Eplontersen (TTR)
ATTRv-PN
Phase 3 data (week 35, 66 & 85)
Olezarsen (APOCIII)
FCS
Phase 3 data
Donidalorsen (PKK)
HAE
Phase 2, OLE 1-year data
Donidalorsen (PKK)
HAE
Phase 2, OLE 2-year data
Bepirovirsen
HBV
Phase 2b B-Together data
IONIS-FB-LRx
IgAN
Phase 2 interim data

Enrollment Achievements
Program
Indication
Event
Achieved
Eplontersen (TTR)
ATTR-CM
Phase 3 full enrollment
Donidalorsen (PKK)
HAE
Phase 3 full enrollment
IONIS-FB-LRx
GA
Phase 2 full enrollment
ION582 (UBE3A)
Angelman syndrome
Phase 1/2 full enrollment

Phase 3 Initiations
Program
Indication
Achieved
Zilganersen (GFAP)
Alexander disease
Bepirovirsen
HBV
IONIS-FB-LRx
IgAN

  (1)
Timing expectations based on current assumptions and subject to change.

(2)
CHMP opinion anticipated in Q4:2023.


10
 EX-101.SCH 3 ions-20231102.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ions-20231102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 ions-20231102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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image1.jpg begin 644 image1.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 02, 2023
Entity File Number 000-19125
Entity Registrant Name IONIS PHARMACEUTICALS, INC
Entity Central Index Key 0000874015
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 33-0336973
Entity Address, Address Line One 2855 Gazelle Court
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92010
City Area Code 760
Local Phone Number 931-9200
Title of 12(b) Security Common Stock, $.001 Par Value
Trading Symbol “IONS”
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 9 ef20013902_8k_htm.xml IDEA: XBRL DOCUMENT 0000874015 2023-11-02 2023-11-02 false 0000874015 8-K 2023-11-02 IONIS PHARMACEUTICALS, INC DE 000-19125 33-0336973 2855 Gazelle Court Carlsbad CA 92010 760 931-9200 false false false false Common Stock, $.001 Par Value “IONS” NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://ionispharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20013902_8k.htm ions-20231102.xsd ions-20231102_lab.xml ions-20231102_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20013902_8k.htm": { "nsprefix": "ions", "nsuri": "http://ionispharma.com/20231102", "dts": { "inline": { "local": [ "ef20013902_8k.htm" ] }, "schema": { "local": [ "ions-20231102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "ions-20231102_lab.xml" ] }, "presentationLink": { "local": [ "ions-20231102_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://ionispharma.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231102to20231102", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20013902_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231102to20231102", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20013902_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ionispharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-23-051047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-051047-xbrl.zip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